Human papillomavirus antibodies and future risk of anogenital cancer: A nested case-control study in the European Prospective Investigation into Cancer and Nutrition study

Aimée R. Kreimer, Paul Brennan, Krystle A. Lang Kuhs, Tim Waterboer, Gary Clifford, Silvia Franceschi, Angelika Michel, Martina Willhauck-Fleckenstein, Elio Riboli, Xavier Castellsagué, Allan Hildesheim, Renée Turzanski Fortner, Rudolf Kaaks, Domenico Palli, Ingrid Ljuslinder, Salvatore Panico, Franc¸oise Clavel-Chapelon, Marie Christine Boutron-Ruault, Sylvie Mesrine, Antonia TrichopoulouPagona Lagiou, Dimitrios Trichopoulos, Petra H. Peeters, Amanda J. Cross, H. Bas Bueno-de-Mesquita, Paolo Vineis, Nerea Larrañaga, Valeria Pala, María José Sánchez, Carmen Navarro, Aurelio Barricarte, Rosario Tumino, Kay Tee Khaw, Nicholas Wareham, Heiner Boeing, Annika Steffen, Ruth C. Travis, J. Ramón Quirós, Elisabete Weiderpass, Michael Pawlita, Mattias Johansson

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Human papillomavirus (HPV) type 16 (HPV16) causes cancer at several anatomic sites. In the European Prospective Investigation Into Cancer and Nutrition study, HPV16 E6 seropositivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in controls. The current study sought to evaluate the extent to which HPV16 E6 antibodies are present before diagnosis of anogenital cancers within the same cohort. Methods: Four hundred incident anogenital cancers (273 cervical, 24 anal, 67 vulvar, 12 vaginal, and 24 penile cancers) with prediagnostic blood samples (collected on average 3 and 8 years before diagnosis for cervix and noncervix cancers, respectively) and 718 matched controls were included. Plasma was analyzed for antibodies against HPV16 E6 and multiple other HPV proteins and genotypes and evaluated in relation to risk using unconditional logistic regression. Results: HPV16 E6 seropositivity was present in 29.2% of individuals (seven of 24 individuals) who later developed anal cancer compared with 0.6% of controls (four of 718 controls) who remained cancer free (odds ratio [OR], 75.9; 95% CI, 17.9 to 321). HPV16 E6 seropositivity was less common for cancers of the cervix (3.3%), vagina (8.3%), vulva (1.5%), and penis (8.3%). No associations were seen for non-type 16 HPV E6 antibodies, apart from anti-HPV58 E6 and anal cancer (OR, 6.8; 95% CI, 1.4 to 33.1). HPV16 E6 seropositivity tended to increase in blood samples drawn closer in time to cancer diagnosis. Conclusion: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.

Original languageEnglish
Pages (from-to)877-884
Number of pages8
JournalJournal of Clinical Oncology
Volume33
Issue number8
DOIs
Publication statusPublished - Mar 10 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Human papillomavirus antibodies and future risk of anogenital cancer: A nested case-control study in the European Prospective Investigation into Cancer and Nutrition study'. Together they form a unique fingerprint.

Cite this